HPV epidemiologic study in Bengbu, China, involving 123,808 women, 2014–2023 Authors: Xiaowen Hu, Manman Zhu, Liqun Wang, Kang Yang, Tao Xu, Yu He Published: 2026 ABSTRACT AbstractBackgroundCervical cancer is largely caused by persistent high-risk human papillomavirus infection, and due to the wide regional variations in HPV type distribution, the long-term epidemiological characterization of HPV infection in China has not yet been sufficiently studied. Cervical cancer screening and the creation of HPV vaccination programs in a given area are significantly influenced by the epidemiological features of HPV infection in that area. In order to provide an epidemiological foundation for the development of an early screening and prevention strategy for cervical cancer, we examined the epidemiological features of HPV infection in a community in the northern part of Anhui Province, China, in this research.MethodsThis study examined 123,808 cervical exfoliated cell samples that were taken from female patients at Bengbu Medical University’s First Affiliated Hospital between January 2013 and December 2023. An HPV genotyping kit was used for HPV-DNA testing. Age, year, and numerous patterns of HPV infection were taken into consideration when analyzing the prevalence of HPV infection. Differences in prevalence between years and age categories were compared using the χ2 test. Multivariable logistic regression models were used to assess the associations of age, calendar year, and their interaction with the risk of infection by different HPV types, with adjustment for potential confounding factors.ResultsThe detection rate of high-risk types (HR-HPV) was 14.24% (17,630/123,808), while the overall prevalence of HPV infection for the 28 HPV genotypes was 17.62% (21,674/123,808). The age-specificity of HPV infection displayed a bimodal distribution with two distinct peaks: 17.39% of people under 25 had an infection, while 21.14% of people between the ages of 60 and 64 had an infection. According to annual distribution statistics, the overall prevalence of HPV infection was low in 2014 and 2015, rapidly increased to 24.19% (2573/10637) in 2016, peaked at 27.04% (2238/8278) in 2017, then decreased annually to a low of 13.44% (2178/16207) in 2019, and remained relatively stable until 2023, when it increased once more to 17.62% (2545/11443). The top five HR-HPV prevalence rates, according to the study of genotype-specific statistics, were HPV-16 (4.01%, 4968/123808), -52 (2.95%, 3651/123808), -58 (2.12%, 2629/123808), -56 (1.05%, 1298/123808), and 51(0.98%,1216/123808). The most prevalent form of infection among the positive cases was HPV, with a single infection rate of 72.85% (12844/17630). Age was positively associated with infection risk for HPV16, HPV31, HPV33, HPV35, HPV52, HPV56, HPV58, and HPV68 (OR = 1.12–1.26). Infection risks for the majority of HPV types declined significantly over time (OR = 0.57–0.82). Significant age-by-year interaction effects were observed for 10 types, indicating heterogeneity in temporal trends across age groups.ConclusionThis study offers the most comprehensive information on the epidemiological features of HPV infection in Bengbu and even in northern Anhui Province. It also serves as a foundation for the development of cervical cancer prevention and control measures in this area.Keywords: Human papillomavirus(HPV), Epidemiology, Genotype Introduction Cervical cancer is the second most common malignancy among women, following breast cancer. In certain underdeveloped countries, it is the predominant source of cancer incidence, although in affluent nations, its prevalence is markedly lower than that of breast, endometrial, and ovarian cancers. The Global Cancer Burden Report 2020 from the International Agency for Research on Cancer (IARC) indicates that there were 604,127 new cervical cancer cases globally in 2020, with 109,741 cases (18.16%) reported in China. That year, there were 341,831 fatalities attributable to cervical cancer, with 59,060 (17.28%) occurring in China [1]. The World Health Organization (WHO) forecasts that from 2018 to 2030, annual new cases would escalate from 570,000 to 700,000, and annual fatalities will rise from 311,000 to 400,000. Significantly, more than 85% of impacted individuals are young women with less education residing in the world’s most destitute areas, with 88.1% of new cases and 91.4% of fatalities occurring in low- and middle-income countries (LMICs) [2]. Cervical cancer is presently the sole tumor with a definitively documented etiology that is susceptible to early prevention and management. A persistent infection with high-risk human papillomavirus (HR-HPV) is the principal etiological factor in its etiology [3]. Human papillomavirus (HPV) is categorized into “low-risk” (LR-HPV) and “high-risk” (HR-HPV) types based on oncogenic potential. The International Agency for Research on Cancer (IARC) classifies 12 high-risk types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) as Group 1 carcinogens, while HPV 68 is designated as Group 2 A (probably carcinogenic). Types HPV 26, 53, 66, 67, 70, 73, and 82 are categorized as Group 2B (possibly carcinogenic) [4]. The 2022 Chinese Clinical Guidelines for Cervical Cancer Diagnosis and Treatment explicitly identify HR-HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68 as clinically significant for cervical carcinogenesis, with HPV16 and 18 demonstrating the strongest epidemiological association (adjusted OR 23.1–35.7) [4]. Contemporary epidemiological studies confirm that > 80% of sexually active women acquire ≥ 1 h-HPV type during their lifetime. However, 90% of infections are transient, resolving spontaneously through cell-mediated immunity within 12–24 months without oncogenic progression [5]. Persistent HR-HPV infection (defined as detection of the same type for > 24 months) constitutes a necessary precondition for cervical intraepithelial neoplasia (CIN) and invasive carcinoma development [5]. The primary prevention of cervical cancer is now universally recognized as fundamentally reliant on HPV vaccination. The first-generation bivalent (HPV16/18) and quadrivalent (HPV6/11/16/18) vaccinations, launched worldwide in 2006, exhibit over 90% efficacy against new HPV16/18 infections and related high-grade lesions in clinical trials [6]. Chinese women received access to HPV vaccination roughly ten years later than their international peers due to regulatory, sociocultural, and supply-chain obstacles. Notwithstanding the recent surge in immunization initiatives (2017–2022), vaccination coverage in China continues to be 4–6 times inferior to that of high-income nations. Present estimations suggest:3% coverage among females aged 9 to 45 years;1% coverage within the target population of school-aged females (ages 10–14) [7]. The increasing global implementation of cervical cancer screening programs has resulted in a corresponding decrease in both incidence and fatality rates. The World Health Organization (WHO) advocates using HPV genotyping as the principal screening method, wherein HPV-positive people are subjected to triage via sequential cervical cytology (Pap smear), colposcopy, and histological assessment to ascertain clinical status [8]. Current triage techniques for HPV-positive women, are deficient in substantial information about their long-term predictive values and cost-effectiveness ratios. China, a large nation, comprises approximately one-fifth of the global population. It significantly contributes to the worldwide cancer burden, with a notable prevalence of cervical cancer among women. Recent trends indicate a gradual decrease in the average age of onset for this disease, reflecting a concerning shift towards younger demographics [9]. Research indicates that incidence and mortality rates are elevated in rural regions compared to urban areas, with central China exhibiting the highest rates, followed by northwestern China, and northern China showing the lowest rates [10]. China, as a developing nation with a significant population, low vaccine coverage, extensive territory, and uneven economic development, exhibits geographically and temporally varying epidemiologic characteristics of HPV. Consequently, the cancer burden across different regions of China requires further investigation. The HPV vaccine is classified as a non-immunization planning vaccine in China. In the context of the accelerating efforts to eliminate cervical cancer, there exists a significant disparity between the public’s demand for health knowledge and services and the local supply of medical and health resources across various geographic regions. This situation necessitates the development of comprehensive cervical cancer prevention and control plans that are tailored to the economic conditions and health service capacities of different areas in China. Consequently, we determined Bengbu Medical University in Anhui Province, East China, to conduct a prolonged study with a large sample size aimed at investigating the epidemiological characteristics of HPV infection in economically underdeveloped regions. This research aims to provide data support for developing a strategy to guide HPV-targeted vaccination and implement a regional cervical cancer prevention program. Subjects and methods Study population We conducted a retrospective cohort study of 123,808 women who underwent HPV genotyping screening at the gynecological outpatient clinic of the First Affiliated Hospital of Bengbu Medical University between January 2014 and December 2023. This represents a mixed clinical cohort, including both symptomatic patients seeking consultation and asymptomatic individuals attending for cervical cancer screening or routine check-ups. This composition reflects the real-world patient flow in a tertiary hospital setting.Key Characteristics: Age range: 14–95 years (mean ± SD: 42.91 ± 10.77 years). All participants had sexual activity history. Complete HPV genotyping results available. Pre-sampling Requirements: [1] no sexual intercourse within 48 h; [2] no intravaginal medication use within 48 h; [3] sampling conducted during non-menstrual phase. Exclusion Criteria: [1] Pregnancy at time of testing; [2] Incomplete demographic/report data (e.g., missing collection dates). This study was approved by the Ethics Committee of Bengbu Medical University (Approval No. BMU-IRB-2024-418) with waived informed consent due to retrospective anonymized data analysis. Methodology Reagents and Instruments The HPV typing test kit produced by Guangzhou LBP Medicine Science & Technology Co., Ltd. is capable of detecting 19 and 28 types of HPV(NMPA: 201472300638). Between 2014 and June 2016, a total of 19 HPV types were identified, comprising high-risk types such as HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68, as well as low-risk types including HPV53, 66, CP8304, 6, 11, and 43. Between July 2016 and 2023, 28 types were identified. As of December, a total of 28 types were utilized, with the addition of 9 HPV types: HPV73, 82, 26, 40, 42, 44, 54, 61, and 83. DA8000 Fully Automated Nucleic Acid Molecular Hybridization Instrument (Shanghai Medical University Instrument Co., Ltd) and Hema3200 Gene Amplification Instrument (DA8000 Automatic Nucleic Acid Molecular Hybridizer (Shanghai Medical University Instrument Co., Ltd) and Hema3200 Gene Amplifier (Zhuhai Heima Medical Instrument Co., Ltd). Collection and processing of specimens Participants were required to meet the following pre-procedure criteria: [1] non-menstrual status; [2]48-hour abstinence from: (a) sexual intercourse; (b) vaginal douching/irrigation; (c) intravaginal suppository use; (d) vaginal/pelvic examinations. Collection Procedure: [1] cervical mucus removal: Excess mucus was cleared using sterile cotton swabs; [2] cellular sampling: A cervical brush was inserted into the endocervical canal. Rotation protocol: [1]6–8 clockwise rotations at the cervical transformation zone; [2] maintained contact time: ≥10 s; [3] specimen preservation: brush head was immediately placed in cellular preservation medium. HPV-DNA detection HPV-DNA detection was performed using the manufacturer’s protocol. Multiple infections were defined as the concurrent detection of ≥ 2 HPV genotypes in a single sample and were counted cumulatively. The triphasic methodology included DNA extraction via silica-based column purification, PCR amplification using the Hema 9600 Thermal Cycler (Zhuhai Hema Medical Instruments Co., Ltd.), and reverse hybridization with the DA8000 Automated System (Shanghai Medical University Instrument Co., Ltd.). The PCR protocol included an initial activation step of uracil-DNA glycosylase (UDG) at 50 °C for 15 min to mitigate carryover contamination, succeeded by a denaturation phase at 95 °C for 10 min. Amplification was conducted over 40 cycles, comprising denaturation at 94 °C for 30 s, annealing at 42 °C for 90 s, and extension at 72 °C for 30 s, followed by a final extension at 72 °C for 5 min. The results of hybridization were analyzed based on the presence of genotype-specific blue dots: single infections indicated a single positive locus, whereas multiple dots signified concurrent types. Rigorous quality controls included β-globin internal controls (IC) on each membrane, HPV16 plasmid-positive controls (1 × 10³ copies/µL), and nuclease-free water as negative controls. The assay was performed in strict accordance with the instructions of the commercially available HPV Genotyping Detection Kit. Statistical analysis Data normality was assessed by Shapiro-Wilk test. Comparisons between the two groups were made using unpaired Student’s t-test (based on the F-test results assuming chi-square), and comparisons of sample rates between groups were made using chi-square test. The temporal trends (2014–2023) were analyzed using Joinpoint regression. Age, year, and their interaction effects were analyzed using multivariable logistic regression models. Significance markers were *P < 0.05, **P < 0.01, and ***P < 0.001, and all statistical analyses were done using Prism 9 (GraphPad), R4.5.0, Joinpoint5.2.0 and SPSS 26.0 (IBM) software. Results Overall prevalence of HPV infection This study analyzed 123,808 women (age range: 14–95 years; mean ± SD: 42.91 ± 10.77) screened for 28 HPV genotypes (13 high-risk [HR-HPV], 15 low-risk [LR-HPV]) at the First Affiliated Hospital of Bengbu Medical University from 2014 to 2023. The overall HPV infection rate was 18.80% (23273/123,808), with HR-HPV and LR-HPV prevalence rates of 14.24% (17,630/123,808) and 4.56% (5,643/123,808), respectively. Temporal analysis revealed significant fluctuations in total HPV prevalence (Cochran-Armitage χ² = 124.35, *p* < 0.001), peaking at 27.04% (2,238/8,278) in 2017 after a sharp rise from 16.02% in 2014, followed by a nadir of 13.44% (2,178/16,207) in 2019 and a rebound to 17.62% (2,545/11,443) by 2023. Similar trends were observed for HR-HPV (21.5% in 2017 declining to 10.09% in 2019, then rising to 13.4% in 2023) and LR-HPV (peak of 8.35% in 2017 decreasing to 5.35% in 2023; Fig. 1). The overall HPV prevalence peaked in 2017 (27.04%, 95% CI: 26.1%-28.0%) and declined to a nadir in 2019 (13.44%, 95% CI: 12.9%-14.0%). The absolute decrease of 13.60% points was statistically significant (95% CI for the difference: 12.3 to 14.9% points; P < 0.001).Among 22,121 HPV-positive cases (including multiple infections), the predominant HR-HPV types were HPV-16 (4.01%, 4,968/123,808), HPV-52 (2.95%, 3,651/123,808), and HPV-58 (2.12%, 2,627/123,808), with HPV − 56, -51, -68and − 18 following in prevalence (Fig. 2). Joinpoint regression analysis identified distinct temporal trends in HPV type prevalence from 2014 to 2023 (Fig. 3). For HPV16, one significant joinpoint was identified in 2019.3 (approximately mid‑2019). From 2014 to this joinpoint, the annual percent change (APC) was − 14.47% (95% CI: − 22.75% to − 5.31%, P = 0.0094), indicating a statistically significant decline. Thereafter, from 2019 to 2023, the trend reversed with an APC of + 1.07% (95% CI: − 16.45% to 22.26%, P = 0.8955), which was not statistically significant.For HPV52, one joinpoint was detected in 2016.0. During the first segment (2014–2016), the APC was + 28.53% (95% CI: − 33.60% to 148.81%, P = 0.3884), not significant. In the second segment (2016–2023), the APC was − 7.46% (95% CI: − 13.89% to − 0.54%, P = 0.039), indicating a significant decreasing trend. For HPV58, one joinpoint was identified in 2016.0. The APC was + 9.13% (P = 0.7782) from 2014 to 2016, then − 6.97% (95% CI: − 14.05% to 0.70%, P = 0.0672) from 2016 to 2023, showing a borderline non-significant decline. HPV16 remained the most prevalent type despite a slight overall decline. In contrast, HPV18, 35, 39, 51, 56, 59, and 68 showed consistently low detection rates (≤ 1.05% each) over the study period, while HPV52 and HPV58 demonstrated notably higher prevalence (2.95% and 2.12%, respectively). HPV33 prevalence fluctuated, peaking intermittently between 2016 and 2020 before declining in 2023, indicating dynamic shifts in type distribution over the period. Prevalence of HPV infection over the 10 years. Any - HPV: any of 28 detected types; HR-HPV: high-risk types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68); LR-HPV: low-risk types (HPV53, 66, 6, 11, 43, 73, 26, 40, 42, 44, 54, 61, 82, 83 and CP8304.) Prevalence ranking of HR-HPV types(HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,68) Joinpoint regression analysis identified distinct temporal trends in HPV type prevalence from 2014 to 2023 Single and multiple HPV infections In a cohort of 23,273 HPV-positive cases, single HPV infections were identified in 13.09% (16,206/123,808) of the total population. High-risk HPV (HR-HPV) monoinfections constituted 10.37% (12,844/123,808), which corresponds to 72.85% (12,844/17,630) of all HR-HPV-positive cases, thereby establishing single infections as the primary mode of HR-HPV transmission. The prevalence of multiple infections was found to be 4.08% (5,054/123,808), with HR-HPV-involved multiple infections accounting for 3.85% (4,786/123,808) of the total cohort and 27.15% (4,786/17,630) of HR-HPV-positive individuals. In a study of 5,054 cases of HR-HPV-associated multiple infections, dual HR-HPV infections were the most common, comprising 52.79% (2,668/5,054). This was followed by co-infections of single HR-HPV with low-risk HPV (LR-HPV) at 31.64% (1,599/5,054), infections with ≥ 3 h-HPV types at 10.27% (519/5,054), and exclusively LR-HPV multiple infections at 5.30% (268/5,054) (Table 1). Among HR-HPV types, the five genotypes with the highest multiple infection rates were HPV59 (60.69%, 230/379), HPV56 (58.40%, 758/1,298), HPV68 (51.77%, 556/1,074), HPV45(51.3%,59/115) and HPV39 (48.95%,368/470) demonstrating significant co-infection propensities (Fig. 4). Table 1Prevalence of infection patterns of 28 genotypes from 2014 to 2023Positivecases%(95%CI)2014(n = 6606)2015(n = 9511)2016(n = 10637)2017(n = 8278)2018(n = 11156)2019(n = 16207)2020(n = 13129)2021(n = 16706)2022(n = 17135)2023(n = 14443)χ2 P FDRPositive cases17,63014.24(14.05–14.44)1058(16.02)1352(14.22)2132(20.04)1780(21.5)1532(13.73)1774(10.95)1858(14.15)2203(13.19)2005(11.7)1936(13.4)928.27< 0.001< 0.001Infection typesSingle H12,84410.37(10.21–10.55)819(12.4)1078(11.33)1449(13.62)1159(14)1214(10.88)1326(8.18)1326(10.1)1592(9.53)1495(8.72)1386(9.6)160.881< 0.001< 0.001Single L33622.72(2.63–2.81)97(1.47)417(4.38)274(2.58)333(4.02)222(1.99)324(2)317(2.41)450(2.69)437(2.55)491(3.4)222.499< 0.001< 0.001HR + HR26682.15(2.08–2.24)187(2.83)213(2.24)363(3.41)340(4.11)185(1.66)239(1.47)275(2.09)342(2.05)266(1.55)258(1.79)76.19< 0.001< 0.001HR + LR15991.29(1.23–1.36)12(0.18)14(0.15)236(2.22)233(2.81)102(0.91)164(1.01)186(1.42)226(1.35)190(1.11)236(1.63)264.653< 0.001< 0.001LR + LR2680.22(0.19–0.24)1(0.02)1(0.01)2(0.02)56(0.68)41(0.37)25(0.15)34(0.26)38(0.23)27(0.16)43(0.3)112.896< 0.001< 0.001≥ 3 h5190.42(0.38–0.46)40(0.61)47(0.49)84(0.79)48(0.58)31(0.28)45(0.28)71(0.54)43(0.26)54(0.32)56(0.39)36.268< 0.001< 0.001 Prevalence of infection patterns of 28 genotypes from 2014 to 2023 HPV genotypes distribution of single (in blue) and multiple infections (in red) Age-specific prevalence of HPV infection The study population was stratified into 10 age groups: <25, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, and ≥ 65 years. A significant difference in HR-HPV prevalence was observed across age groups (χ² = 387.42, *p* < 0.001), exhibiting a bimodal U-shaped distribution. The first prevalence peak occurred in women < 25 years (17.39%, 607/3,491), followed by a decline to the lowest rate in the 30–34 age group (12.45%, 2,014/16,171). Prevalence subsequently increased with age, reaching a second peak in the 60–64 age group (21.14%, 707/3,345). Among the 123,808 participants, the age distribution was as follows: <25 years (3.44%, 3,491/123,808), 25–29 years (7.38%, 9,985/123,808), 30–59 years (80.27%, 102,464/123,808), 60–64 years (4.01%, 3,344/123,808), and ≥ 65 years (4.66%, 4,166/123,808) (Fig. 5).The first prevalence peak was observed in women < 25 years (17.39%), and the second, higher peak was in women aged 60–64 years (21.14%). The prevalence was significantly higher in the 60–64 year group by 3.75% points (95% CI: 1.9 to 5.6% points; P < 0.001). The prevalence of HPV infection by age groups. HPV infections from 2013 to 2023 From 2014 to 2023, HPV infection rates consistently exhibited a bimodal U-shaped age-specific distribution across all 13 high-risk (HR) genotypes, infection patterns (single, multiple), and annual cohorts (P < 0.001 for all trends; Figs. 5 and 6). The first prevalence peak was observed in women < 25 years (overall: 17.39%, 607/3,491), followed by a decline to a plateau and subsequent rise starting at ages 45–49, culminating in a second peak at 60–64 years (21.14%, 707/3,345). Annual variations were notable: in 2014, the initial peak shifted to the 30–34 age group (16.84%), with lower rates in < 25-year-olds (14.01%), while in 2015, the first peak remained at 30–34 years (14.98%), marginally differing from the < 25-year group (14.02%, χ² = 152.61, P < 0.001), and the second peak occurred in ≥ 65-year-olds (25.60%). This bimodal trend persisted across infection categories: total infections (< 25 years: 17.39%, 607/3,491; 60–64 years: 21.14%, 707/3,345), HR-HPV monoinfections (< 25 years: 10.05%, 88/868; 60–64 years: 13.30%, 445/3,345), single HR-HPV and low-risk (LR) HPV co-infections (< 25 years: 2.35%, 82/868; 60–64 years: 2.48%, 83/3,345), dual HR-HPV infections (< 25 years: 3.90%, 136/868; 60–64 years: 3.95%, 132/3,345), and infections involving ≥ 3 h-HPV types (< 25 years: 1.09%, 38/868; 60–64 years: 1.41%, 47/3,345)(Fig. 6). These findings underscore age-dependent immunological and behavioral risk factors, with heightened susceptibility in younger and older cohorts to both incident and persistent infections. Prevalence of HPV infection types in age groups Distribution of HPV genotypes From 2014 to 2023, the prevalence of the 16 h-HPV genotypes was observed in the following descending order: HPV16, 52, 58, 56, 51, 68, 33, 18, 39, 31, 35, 59 and 45. Significant variations in genotype-specific prevalence were observed across annual cohorts, infection patterns, and age-stratified groups(Figs. 6 and 7; Tables 2, 3 and 4). Prevalence of HPV types in age groups Table 2type-specific prevalence from 2014 to 2023HPV typePositive case%(95%CI)2014(n = 6606)2015(n = 9511)2016(n = 10637)2017(n = 8278)2018(n = 11156)2019(n = 16207)2020(n = 13129)2021(n = 16706)2022(n = 17135)2023(n = 14443)χ2 P FDR1649684.01(3.9–4.12)437(6.62)526(5.53)620(5.83)517(6.25)441(3.95)433(2.67)417(3.18)552(3.3)543(3.17)482(3.34)246.028< 0.001< 0.0015236512.95(2.86–3.04)170 (2.57)259 (2.72)471 (4.43)382 (4.61)337 (3.02)409 (2.52)396 (3.02)432 (2.59)376 (2.19)419 (2.90)219.06< 0.001< 0.0015826292.12(2.04–2.21)166(2.51)198(2.08)325(3.06)277(3.35)207(1.86)287(1.77)305(2.32)304(1.82)298(1.74)262(1.81)14.6930.10.15317941.45(1.38–1.52)140(2.12)105(1.1)211(1.98)159(1.92)167(1.5)190(1.17)199(1.52)228(1.36)206(1.2)189(1.31)33.081< 0.001< 0.0015612981.05(0.99–1.11)79(1.2)109(1.15)146(1.37)139(1.68)85(0.76)131(0.81)149(1.13)163(0.98)154(0.9)143(0.99)15.1260.0880.0915112160.98(0.93–1.04)48(0.73)77(0.81)162(1.52)131(1.58)122(1.09)129(0.8)135(1.03)160(0.96)133(0.78)119(0.82)25.9420.0020.0036810740.87(0.82–0.92)131(1.98)102(1.07)137(1.29)118(1.43)73(0.65)74(0.46)108(0.82)109(0.65)109(0.64)113(0.78)105.618< 0.001< 0.0013310300.83(0.78–0.88)86(1.3)88(0.93)125(1.18)116(1.4)65(0.58)91(0.56)107(0.81)119(0.71)117(0.68)116(0.8)24.1850.0040.005669770.79(0.74–0.84)84(1.27)111(1.17)149(1.4)96(1.16)65(0.58)78(0.48)94(0.72)115(0.69)89(0.52)96(0.66)59.394< 0.001< 0.001189490.77(0.72–0.82)41(0.62)35(0.37)100(0.94)59(0.71)66(0.59)116(0.72)122(0.93)153(0.92)127(0.74)130(0.9)77.033< 0.001< 0.001397400.6(0.56–0.64)30(0.45)43(0.45)124(1.17)80(0.97)42(0.38)50(0.31)77(0.59)117(0.7)91(0.53)86(0.6)49.716< 0.001< 0.001315720.46(0.43–0.5)34(0.51)33(0.35)93(0.87)67(0.81)21(0.19)32(0.2)70(0.53)89(0.53)68(0.4)65(0.45)50.564< 0.001< 0.001355230.42(0.39–0.46)39(0.59)37(0.39)76(0.71)54(0.65)52(0.47)60(0.37)63(0.48)65(0.39)32(0.19)45(0.31)22.9730.0060.007593790.31(0.28–0.34)27(0.41)44(0.46)61(0.57)37(0.45)16(0.14)11(0.07)43(0.33)37(0.22)40(0.23)63(0.44)60.31< 0.001< 0.001822060.17(0.15–0.19)N/AN/A33(0.31)39(0.47)21(0.19)31(0.19)26(0.2)24(0.14)14(0.08)18(0.12)52.331< 0.001< 0.001451150.09(0.08–0.11)11(0.17)16(0.17)21(0.2)11(0.13)7(0.06)8(0.05)9(0.07)8(0.05)13(0.08)11(0.08)47.222< 0.001< 0.0014221301.72(1.65–1.79)N/AN/A105(0.99)122(1.47)92(0.82)1046(6.45)139(1.06)217(1.3)198(1.16)211(1.46)3187.578< 0.001< 0.001CP83049660.78(0.73–0.83)47(0.71)68(0.71)142(1.33)86(1.04)65(0.58)96(0.59)90(0.69)131(0.78)103(0.6)138(0.96)25.0820.0030.004449400.76(0.71–0.81)N/AN/A153(1.44)127(1.53)67(0.6)90(0.56)113(0.86)118(0.71)115(0.67)157(1.09)186.294< 0.001< 0.001617630.62(0.57–0.66)N/AN/A94(0.88)105(1.27)55(0.49)94(0.58)81(0.62)90(0.54)101(0.59)143(0.99)158.204< 0.001< 0.00166300.51(0.47–0.55)33(0.5)54(0.57)52(0.49)59(0.71)45(0.4)56(0.35)73(0.56)86(0.51)89(0.52)83(0.57)29.556< 0.001< 0.001545820.47(0.43–0.51)N/AN/A85(0.8)94(1.14)28(0.25)44(0.27)66(0.5)95(0.57)68(0.4)102(0.71)147.387< 0.001< 0.001405380.43(0.4–0.47)N/AN/A101(0.95)118(1.43)63(0.56)54(0.33)52(0.4)64(0.38)43(0.25)43(0.3)177.837< 0.001< 0.001113460.28(0.25–0.31)36(0.54)45(0.47)36(0.34)52(0.63)28(0.25)18(0.11)29(0.22)43(0.26)31(0.18)28(0.19)52.651< 0.001< 0.001433030.24(0.22–0.27)17(0.26)35(0.37)55(0.52)43(0.52)6(0.05)13(0.08)23(0.18)49(0.29)29(0.17)33(0.23)53.972< 0.001< 0.00126980.08(0.06–0.1)N/AN/A14(0.13)19(0.23)7(0.06)4(0.02)12(0.09)13(0.08)15(0.09)14(0.1)28.999< 0.001< 0.00173530.04(0.03–0.06)N/AN/A7(0.07)10(0.12)4(0.04)3(0.02)8(0.06)12(0.07)3(0.02)6(0.04)19.9620.0180.0283500.04(0.03–0.05)N/AN/A9(0.08)7(0.08)0(0)6(0.04)9(0.07)5(0.03)3(0.02)11(0.08)22.2910.0080.009 type-specific prevalence from 2014 to 2023 Table 3prevalence of single and multiple HR-HPV infectionsHPV genotypeSingle infectionMultiple infectionsTotal infectionPositive case%(95%CI)Positive case%(95%CI)Positive case%(95%CI)1636302.93(2.84–3.03)13381.08(1.02–1.14)49684.01(3.9–4.12)5222371.81(1.73–1.88)14141.14(1.08–1.2)36512.95(2.86–3.04)5815701.27(1.21–1.33)10590.86(0.81–0.91)26292.12(2.04–2.21)538970.72(0.68–0.77)8970.72(0.68–0.77)17941.45(1.38–1.52)565400.44(0.4–0.47)7580.61(0.57–0.66)12981.05(0.99–1.11)516560.53(0.49–0.57)5600.45(0.42–0.49)12160.98(0.93–1.04)685180.42(0.38–0.46)5560.45(0.41–0.49)10740.87(0.82–0.92)336200.5(0.46–0.54)4100.33(0.3–0.36)10300.83(0.78–0.88)663900.32(0.29–0.35)5870.47(0.44–0.51)9770.79(0.74–0.84)185580.45(0.41–0.49)3910.32(0.29–0.35)9490.77(0.72–0.82)393720.3(0.27–0.33)3680.3(0.27–0.33)7400.6(0.56–0.64)312920.24(0.21–0.26)2800.23(0.2–0.25)5720.46(0.43–0.5)352690.22(0.19–0.24)2540.21(0.18–0.23)5230.42(0.39–0.46)591490.12(0.1–0.14)2300.19(0.16–0.21)3790.31(0.28–0.34)82900.07(0.06–0.09)1160.09(0.08–0.11)2060.17(0.15–0.19)45560.05(0.03–0.06)590.05(0.04–0.06)1150.09(0.08–0.11)4236302.93(2.84–3.03)13381.08(1.02–1.14)49684.01(3.9–4.12) prevalence of single and multiple HR-HPV infections Table 4prevalence of HR-HPV infection at different age groups among 123,808 females from 2014 to 2023Positive case%(95%CI)<25(n = 3491)25–29(n = 9984)30–34(n = 16171)35–39(n = 17756)40–44(n = 21420)45–49(n = 21924)50–54(n = 17113)55–59(n = 8080)60–64(n = 3345)≥ 65(n = 4166)unknown(n = 358)χ2 P FDRPositive case17,63014.24(14.05–14.44)607(17.39)1301(13.03)2014(12.45)2363(13.31)2865(13.38)2929(13.36)2582(15.09)1398(17.3)707(21.14)822(19.73)42(11.73)429.22< 0.001< 0.001Years201410580.85(0.8–0.91)43(1.23)99(0.99)133(0.82)152(0.86)211(0.99)207(0.94)111(0.65)31(0.38)38(1.14)26(0.62)7(1.96)94.09< 0.001< 0.001201513521.09(1.04–1.15)52(1.49)118(1.18)167(1.03)218(1.23)241(1.13)243(1.11)175(1.02)40(0.5)45(1.35)53(1.27)0(0)72.8< 0.001< 0.001201621321.72(1.65–1.8)99(2.84)218(2.18)242(1.5)334(1.88)396(1.85)364(1.66)278(1.62)74(0.92)71(2.12)55(1.32)1(0.28)148.571< 0.001< 0.001201717801.44(1.37–1.51)54(1.55)159(1.59)208(1.29)263(1.48)346(1.62)330(1.51)203(1.19)88(1.09)61(1.82)59(1.42)9(2.51)78.928< 0.0010.189201815321.24(1.18–1.3)44(1.26)110(1.1)164(1.01)212(1.19)256(1.2)288(1.31)227(1.33)94(1.16)59(1.76)73(1.75)5(1.4)15.2480.1230.333201917741.43(1.37–1.5)45(1.29)115(1.15)203(1.26)227(1.28)299(1.4)307(1.4)287(1.68)144(1.78)67(2)76(1.82)4(1.12)12.5490.25< 0.001202018581.5(1.43–1.57)77(2.21)130(1.3)237(1.47)200(1.13)288(1.34)309(1.41)278(1.62)169(2.09)57(1.7)106(2.54)7(1.96)32.933< 0.001< 0.001202122031.78(1.71–1.85)74(2.12)144(1.44)257(1.59)303(1.71)332(1.55)342(1.56)321(1.88)236(2.92)73(2.18)118(2.83)3(0.84)38.138< 0.001< 0.001202220051.62(1.55–1.69)72(2.06)116(1.16)218(1.35)233(1.31)262(1.22)287(1.31)333(1.95)245(3.03)105(3.14)131(3.14)3(0.84)119.879< 0.001< 0.001202319361.56(1.5–1.63)47(1.35)92(0.92)185(1.14)221(1.24)234(1.09)252(1.15)369(2.16)277(3.43)131(3.92)125(3)3(0.84)277.415< 0.0010.002HPV genotypeHPV1649684.01(3.9–4.12)170(4.87)363(3.64)543(3.36)648(3.65)816(3.81)813(3.71)697(4.07)385(4.76)225(6.73)291(6.99)7(1.96)29.1880.0010.033HPV189500.77(0.72–0.82)45(1.29)90(0.9)92(0.57)115(0.65)143(0.67)156(0.71)123(0.72)78(0.97)45(1.35)59(1.42)0(0)15.70.1090.091HPV315780.47(0.43–0.51)28(0.8)32(0.32)61(0.38)81(0.46)92(0.43)87(0.4)86(0.5)43(0.53)18(0.54)50(1.2)1(0.28)21.0470.0210.086HPV3310220.83(0.78–0.88)40(1.15)77(0.77)110(0.68)129(0.73)177(0.83)151(0.69)135(0.79)85(1.05)50(1.49)68(1.63)9(2.51)18.0070.0550.068HPV355230.42(0.39–0.46)15(0.43)39(0.39)56(0.35)65(0.37)71(0.33)73(0.33)89(0.52)44(0.54)33(0.99)37(0.89)5(1.4)18.3660.0490.086HPV397380.6(0.55–0.64)43(1.23)65(0.65)84(0.52)85(0.48)128(0.6)107(0.49)109(0.64)46(0.57)41(1.23)29(0.7)4(1.12)19.1910.0380.068HPV451180.1(0.08–0.11)7(0.2)12(0.12)17(0.11)16(0.09)18(0.08)18(0.08)15(0.09)9(0.11)2(0.06)4(0.1)7(1.96)109.172< 0.001< 0.001HPV5112150.98(0.93–1.04)54(1.55)113(1.13)146(0.9)175(0.99)185(0.86)166(0.76)178(1.04)94(1.16)51(1.52)51(1.22)3(0.84)17.4360.0650.101HPV5215151.22(1.16–1.29)57(1.63)123(1.23)174(1.08)213(1.2)209(0.98)205(0.94)248(1.45)128(1.58)81(2.42)74(1.78)3(0.84)18.210.0520.089HPV5613621.1(1.04–1.16)49(1.4)111(1.11)152(0.94)168(0.95)195(0.91)226(1.03)183(1.07)138(1.71)74(2.21)63(1.51)3(0.84)16.6640.0820.123HPV5826292.12(2.04–2.21)113(3.24)183(1.83)308(1.9)316(1.78)405(1.89)429(1.96)418(2.44)195(2.41)113(3.38)141(3.38)7(1.96)9.7790.460.529HPV593770.3(0.28–0.34)37(1.06)43(0.43)51(0.32)51(0.29)54(0.25)47(0.21)37(0.22)26(0.32)22(0.66)9(0.22)0(0)58.626< 0.001< 0.001HPV6811050.89(0.84–0.95)50(1.43)54(0.54)146(0.9)138(0.78)174(0.81)203(0.93)135(0.79)95(1.18)51(1.52)52(1.25)1(0.28)28.6380.0010.002HPV5317311.4(1.33–1.47)52(1.49)114(1.14)154(0.95)207(1.17)249(1.16)309(1.41)308(1.8)167(2.07)79(2.36)91(2.18)9(2.51)44.329< 0.001< 0.001HPV669770.79(0.74–0.84)48(1.37)75(0.75)138(0.85)116(0.65)129(0.6)151(0.69)163(0.95)71(0.88)44(1.32)40(0.96)5(1.4)20.3850.0260.039HPV 822060.17(0.15–0.19)16(0.46)13(0.13)28(0.17)32(0.18)30(0.14)29(0.13)20(0.12)13(0.16)8(0.24)17(0.41)4(1.12)32.748< 0.001< 0.001Infection typesSingle H12,84410.37(10.21–10.55)351(10.05)933(9.34)1551(9.59)1825(10.28)2212(10.33)2191(9.99)1832(10.71)953(11.79)445(13.3)519(12.46)32(8.94)238.587< 0.001< 0.001HR + HR26682.15(2.08–2.24)136(3.9)235(2.35)282(1.74)315(1.77)382(1.78)416(1.9)394(2.3)213(2.64)132(3.95)155(3.72)8(2.23)67.181< 0.001< 0.001HR + LR15991.29(1.23–1.36)82(2.35)107(1.07)131(0.81)184(1.04)213(0.99)250(1.14)265(1.55)185(2.29)83(2.48)97(2.33)2(0.56)95.055< 0.001< 0.001≥ 3 h5190.42(0.38–0.46)38(1.09)26(0.26)50(0.31)39(0.22)58(0.27)72(0.33)91(0.53)47(0.58)47(1.41)51(1.22)0(0)123.374< 0.001< 0.001 prevalence of HR-HPV infection at different age groups among 123,808 females from 2014 to 2023 All HR-HPV types showed a bimodal U-shaped age-specific prevalence between 2014 and 2023, albeit there were genotype-dependent differences. Across all types, women under 25 years old consistently experienced the first infection peak. The second prevalence peak for the majority of genotypes (HPV35, 39, 51, 52, 56, 58, 59, 68) appeared in the 60–64 age range: HPV35 (0.99%, 33/3,345), HPV39 (1.23%, 41/3,345), HPV51 (1.52%, 51/3,345), HPV52 (2.42%, 81/3,345), HPV56 (2.21%, 74/3,345), HPV58 (3.38%, 113/3,345), HPV59 (0.66%, 22/3,345), and HPV68 (1.52%, 51/3,345). The ≥ 65 age group, however, showed a clear small secondary peak for HPV16, 18, 31, and 33: HPV16 (6.99%, 291/4,166), HPV18 (1.42%, 59/4,166), HPV31 (1.20%, 50/4,166), and HPV33 (1.63%, 68/4,166) (Fig. 5). With HR-HPV exhibiting remarkable oncogenic resistance in elderly populations, these disparate aging trends point to biological persistence mechanisms specific to types(Fig. 7). Multivariable-adjusted associations of age, year, and their interaction To assess independent associations after adjusting for potential confounders, we employed multivariable logistic regression models to analyze the relationships of age, calendar year, and their interaction with the risk of infection by different HPV types. Age Effect: Increasing age was significantly associated with a higher risk of infection for multiple HR- HPV types, including HPV16 (adjusted OR [aOR] = 1.15, 95% CI: 1.11–1.19), HPV31 (aOR = 1.18, 95% CI: 1.08–1.28), HPV33 (aOR = 1.14, 95% CI: 1.07–1.22), HPV35 (aOR = 1.26, 95% CI: 1.16–1.36), HPV52 (aOR = 1.12, 95% CI: 1.08–1.16), HPV56 (aOR = 1.15, 95% CI: 1.08–1.21), HPV58 (aOR = 1.12, 95% CI: 1.08–1.17), and HPV68 (aOR = 1.12, 95% CI: 1.04–1.20) (all P < 0.01). In contrast, age was negatively associated with the risk of HPV59 infection (aOR = 0.77, 95% CI: 0.68–0.88, P < 0.001). No significant association was found between age and the risk of infection for HPV18, HPV39, HPV45, or HPV51 (P > 0.05). Temporal Trend: A significant declining trend in infection risk over calendar years was observed for most types. The aORs per one-standard-deviation increase in year were 0.57 (95% CI: 0.44–0.75) for HPV45, 0.61 (95% CI: 0.54–0.69) for HPV35, and ranged from 0.64 to 0.82 for HPV51, HPV68, HPV58, HPV33, HPV31, HPV16, HPV56, HPV39, HPV52, and HPV18 (all P < 0.05). No significant temporal trend was observed for HPV59 (aOR = 0.94, 95% CI: 0.81–1.09, P = 0.412). Age-by-Year Interaction Significant interaction effects between age and calendar year were identified for HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV52, HPV56, HPV59, and HPV68 (all P < 0.05), indicating that the temporal decline in infection risk was not uniform across different age groups. The interaction terms for HPV45, HPV51, and HPV58 were not statistically significant. Forest plots visualizing the adjusted associations for age, calendar year, and their interaction term are shown in Figs. 8, 9 and 10, and 11, respectively. Prevalence of HPV infection types in different years Association between age (standardized) and infection with different HR-HPV types (adjusted OR, 95% CI) Association between calendar year (standardized) and infection with different HPV types (adjusted OR, 95% CI) Age–year interaction effect on infection with different HPV types (adjusted OR, 95% CI) Discussion Cervical cancer is a malignancy with a well-established etiology and ranks among the most preventable cancers. Persistent infection with HR-HPV is closely associated with the pathogenesis of cervical cancer and other anogenital malignancies. Carcinogenesis follows a multistep progression from precancerous lesions to invasive carcinoma, providing a critical window for clinical prevention, diagnosis, and treatment. Understanding the epidemiological characteristics of HPV infections in specific regions is essential for constructing effective cervical disease prevention and management systems. To address this, we conducted a large-scale epidemiological study analyzing cervical samples from 123,808 women in Bengbu, Anhui Province, China, collected between 2014 and 2023, to delineate the infection patterns of HPV. The study cohort comprised both gynecological outpatients and asymptomatic women, providing a representative sample of HPV infection patterns among females in Bengbu, Anhui Province. Our study has several limitations. First, the mixed nature of our cohort—comprising both symptomatic and screening patients—may introduce selection bias. The inclusion of symptomatic individuals likely seeking care for gynecological issues could lead to an overestimation of the true population prevalence of HPV. However, this bias is less likely to substantially alter the internal comparisons central to our study, such as the relative age-specific trends.However, significant geographical disparities in HPV prevalence exist across regions and nations globally. From a global perspective, the highest HPV prevalence rates (≥ 33.87%) are observed in parts of Africa, South America, and Eastern Europe, followed by select European countries and Australia (16.93–33.87%), while China and some North/South American nations report lower rates (< 16.93%) [1]. A recent multinational study of over 1 million women without cervical abnormalities revealed the lowest HPV prevalence in West Asia (1.7%) and North America (4.7%), contrasting sharply with the highest rates in East Africa (33.6%) and the Caribbean (35.4%) [11]. Even within China—a country characterized by vast territories and diverse populations—HPV prevalence varies substantially due to geographical location, economic status, and awareness of prevention and early screening. Meta-analyses demonstrate significant regional differences (P < 0.05), with Central China exhibiting the highest prevalence (19.00%), followed by Southwest China (15.67%), and Northwest China having the lowest rates (9.96%) [12]. In this study, the overall HPV prevalence was 17.62%, with high-risk HPV (HR-HPV) infections accounting for 14.24% of cases. This rate is moderately lower than the national pooled estimate for China (15.5%) [13] and meta-analytical findings from mainland Chinese epidemiological studies (19.0%) [14]. Comparatively, our results exceed those reported in Suzhou, Jiangsu Province (10.2%) [15], Wuhan, Hubei Province (13.96%) [16], Xinjiang (14.02%) [17], and Liaoning Province (10.3%) [18], yet remain lower than rates observed in Xiamen (18.4%) [19], Beijing (24.1%) [20], Nanning, Guangxi (19.0%) [21], Guangzhou (21.7%) [22], Zhejiang Province (22.3%) [23], and northern regions such as Heilongjiang (27.1%) [24] and Shandong (18.1%) [25]. These findings position Bengbu, Anhui Province, within the mid-range of HR-HPV prevalence among neighboring regions, suggesting potential for further reduction through targeted interventions. From 2014 to 2023, high-risk HPV (HR-HPV) prevalence in Bengbu, Anhui Province, exhibited marked fluctuations: rising from 16.02% in 2014 to a peak of 21.50% in 2017, followed by a decline to 13.73% in 2018 and stabilization at 13.40% by 2023. Similarly, low-risk HPV (LR-HPV) infections surged from < 3.5% (2014–2015) to 8.35% in 2017 before decreasing to 5.85% in 2023, mirroring the overall HPV prevalence trajectory. The 2017 peak likely reflects enhanced detection due to China’s nationwide “Two Cancers” Screening Program which was piloted in 2009 and actively promoted in Anhui Province from 2014 onward, leading to increased cervical screening uptake, public health awareness, and higher identification of asymptomatic infections [26]. Subsequent declines post-2018 correlate with expanded HPV vaccination coverage, targeted prevention campaigns, and broader inclusion of asymptomatic women in screening programs, aligning observed rates closer to natural infection levels. The COVID-19 pandemic further influenced trends [27]: healthcare disruptions in 2020–2022 prioritized symptomatic/high-risk individuals, temporarily inflating positivity rates, while 2023 declines coincided with restored healthcare access and relaxed social distancing measures. Regional comparisons position Bengbu’s HR-HPV prevalence within China’s mid-range (13.40–21.50%), underscoring the need for sustained screening equity and vaccination efforts to mitigate cervical cancer burden amid evolving public health challenges. We emphasize that this interpretation is speculative and derives from an ecological correlation in time, rather than direct statistical evidence from our data. Notably, the HPV prevalence observed in this study is lower than previously reported rates from a municipal hospital in Bengbu (19.47%) [28]. This discrepancy may be attributed to the smaller sample size of the aforementioned study (16,599 cases), leading to variations in prevalence rates across different studies. This study was a hospital-based survey involving a limited sample of gynecologic patients and women undergoing physical examinations, thus it does not represent the entire female population in Anhui and is not generalizable to the broader population in the region. HPV16 and HPV18 are the leading high-risk genotypes worldwide, accounting for around 70% of cervical cancer cases [1]. The 2023 report from the ICO/IARC Information Centre on HPV and Cancer showed that HPV16 (2.8%), HPV52 (1.5%), HPV53 (1.2%), HPV31 (1.2%), HPV51 (1.1%), and HPV18 (1.1%) were the most common high-risk HPV (hrHPV) types worldwide [29]. However, regional epidemiological variations necessitate localized prevention strategies. In Bengbu, Anhui Province, China, the predominant HR-HPV genotypes were HPV16 (4.01%), 52 (2.95%), 58 (2.12%), 56 (1.05%) and 51(0.98%). HPV18 was ranked 8th (0.78%), reflecting a distribution pattern similar to that observed in mainland China (HPV52 > 16> 58 > 18 > 33) [14]. Regional disparities in China are significant: Guangzhou identifies HPV52 as the most prevalent type, followed by HPV16, 58, 51, and 53 [22]. In contrast, Xiamen, Beijing, Xinjiang, Suzhou, and Southern China emphasize HPV52, 58, and 16 [15, 17, 19, 20, 30]. Shandong Province in Eastern China shows a dominance of HPV16, followed by HPV52, 53, 58, and 51. In Hong Kong, the most prevalent types among women with abnormal cytology are HPV58, 52, 53, 16, and HPV18. The studies indicate that HPV52 and 58 are more prevalent in China’s general population than in developed nations, in contrast to Western countries where HPV31 and 33 are predominant [31]. The regional disparities observed in the top five genotypes indicate geographical variations in HPV epidemiology, likely influenced by factors such as local health awareness, socioeconomic status, and hygiene practices. In the development of region-specific vaccines, it is essential to prioritize these distributional differences. A meta-analysis indicates that in East Asia, HPV52 and 58 are linked to cervical intraepithelial neoplasia (CIN) and invasive carcinoma at rates 2.5–2.8-fold and 3.7–4.9-fold higher, respectively, compared to other regions [32]. Considering the significant prevalence and oncogenic potential of HPV52, 58, 56and 51 in Anhui Province, it is essential that prevention strategies encompass more than just HPV16/18. This should include the development of multivalent vaccines, such as nonavalent formulations, alongside enhanced screening programs. Current HPV vaccines may not adequately correspond to Anhui’s infection profile, highlighting the necessity for the development of region-specific vaccines. The study’s limitations encompass the lack of genotype-specific carcinogenicity analyses and the absence of cytological or histopathological data for HPV-positive cases, which hinders definitive evaluations of cervical disease progression. Future studies will investigate these aspects to refine vaccine design and optimize prevention protocols. The prevalence of multiple HPV infections holds critical significance for understanding their role in cervical carcinogenesis. In this study, single HPV infections represented the most common pattern of HR-HPV infection (10.30%, 12,749/123,808), accounting for 72.38% (12,749/17,615) of all HR-HPV-positive cases, while multiple infections constituted 27.62%—a proportion consistent with reports from Chengdu (26.74%) [29], Guangzhou (26.5%) [22], and Beijing (27.7%) [20], though lower than Xiamen (23.3%) [19] and Zhejiang (22.5%) [23]. The potential impact of multiple infections on cervical pathology remains debated. Some studies suggest that women with multiple infections face significantly higher cervical cancer risks than those with monoinfections: persistent single infections confer a 19.9-fold increased risk compared to HPV-negative individuals, rising to 31.8-fold for multiple infections [33]. Furthermore, multiple HPV infections are identified as a key risk factor for CIN ≥ 2 [34], with co-infections prolonging viral persistence and elevating risks of precancerous lesions and invasive carcinoma [35]. Conversely, other research posits that lesion severity correlates not with infection multiplicity but with specific HPV types [36]; for instance, co-infection with HPV16 and other HR-HPV genotypes does not heighten cancer risk beyond HPV16 monoinfection [37]. Regardless, both scenarios underscore that multiple infections amplify cervical disease risks relative to non-infected states, emphasizing the imperative of vaccination and screening. Notably, HPV16 exhibited the highest monoinfection rate (73.06%), whereas HPV59 demonstrated the highest co-infection prevalence (39.31%). Among 5,054 multiple infection cases, HR-HPV/HR-HPV co-infections predominated (52.79%, 2,668/5,054), followed by HR-HPV/LR-HPV combinations (31.64%, 1,599/5,054), and exclusively LR-HPV co-infections were least frequent (5.30%, 268/5,054). Critically, 28.34% (1,599/5,643) of LR-HPV-positive patients harbored concurrent HR-HPV infections, indicating that individuals with genital warts warrant concurrent HPV screening and tailored management to address potential HR-HPV co-infections. Clinical data indicate that high-risk HPV infections exhibit a clear age specificity. High-risk HPV infections exhibit a prevalence of approximately 30% among young women, particularly those under 25 years of age; however, most of these infections are transient. The prevalence of high-risk HPV infections in women over 30 years decreases significantly; however, it remains low (< 10%) in the 35–44 age range and begins to rise gradually, typically reaching another peak at ≥ 65 years of age [1]. This study investigated HPV infection characteristics among women in northern Anhui Province from 2014 to 2023, revealing trends consistent with prior research. This study indicates that increasing age is associated with a higher risk of infection for most HR- HPV types, particularly HPV35 (OR = 1.26), suggesting that age is an important factor influencing HPV persistence. Notably, HPV59 showed a negative association with age, which may reflect its distinct infection dynamics or population immune differences. High-risk HPV (HR-HPV) infections exhibited a persistent bimodal U-shaped age-specific distribution, albeit with genotype-dependent variations. The first minor peak uniformly occurred in the < 25-year age group, while the second minor peak for most HR-HPV types (e.g., HPV35, 39, 51, 52, 56, 58, 59, 68, 53, 66) emerged in the 60–64-year group. Notably, HPV16, 18, and31 demonstrated a distinct second peak in the ≥ 65-year group, potentially linked to lifestyle factors, sexual activity frequency, and protective measure utilization. Temporal comparisons revealed that in 2014 and 2015, the initial peak shifted to the 30–34-year group, likely reflecting insufficient cervical screening awareness among young women at the time. Subsequent implementation of China’s “Two Cancers” Screening Program and improved public health literacy restored the bimodal U-shaped pattern in later years.The elevated prevalence in younger women (< 25 years) may correlate with immature immune responses and heightened sexual activity, with infection rates reaching 80% in sexually active cohorts [38]. Prevalence declined with age, followed by a gradual rise starting at 31–50 years, and surged markedly in the 60–64 and ≥ 65-year groups. Strikingly, the ≥ 65-year group exhibited the highest HR-HPV prevalence, potentially attributable to immune dysregulation and reactivation of latent HPV infections post-menopause [39]. Similar trends were observed in the overall HPV infection rate and the prevalence of co-infections involving both low-risk (LR-HPV) and high-risk HPV (HR-HPV) types. This study evaluated the frequency of singular and multiple HPV infections across distinct age demographics. The incidence of single HPV infections exceeded that of concurrent HPV infections across all age demographics. The incidence of multiple infections reached its zenith among elderly women (≥ 60 years) at a markedly elevated rate compared to previous levels. Older women demonstrate decreased immunocompetence, leading to a reduced capacity to eliminate both existing and new HPV infections. Highlighting the necessity for enhanced focus and specific initiatives within this demographic. This information may inform the creation of more efficient and focused screening tactics, such as advocating for increased screening frequency or integrating HPV testing into standard screening protocols for this particular demographic. Consequently, our study indicates that enhanced promotion of HPV prevention techniques for young women, together with routine cervical cancer screening for perimenopausal and menopausal women, is essential and beneficial in Anhui. We state that the interpretation of our observed bimodal age pattern is limited by the cross-sectional design, which cannot disentangle true age effects from birth cohort effects, and that the pattern likely represents a confluence of both influences, warranting future longitudinal studies. Regarding temporal trends, infection risks decreased significantly over calendar years for all HR-types except HPV59. Future research should further explore age-specific prevention strategies and investigate the epidemiological characteristics of outlier types such as HPV59. This study synthesizes cervical screening data from 2014 to 2023 at our institution, representing the largest regional epidemiological dataset on HPV infections in northern Anhui Province to date. These findings provide critical clinical evidence to optimize cervical cancer screening protocols and vaccination strategies, establishing a robust foundation for region-specific prevention frameworks. Conclusions This study investigated the epidemiological profile of HPV infections among women in Bengbu, Anhui Province, China, from 2014 to 2023, focusing on age-specific prevalence and genotype distribution. A consistent bimodal age-specific distribution was observed across all age groups, with infection peaks occurring in women aged < 25 years and 60–64 years. The predominant HR-HPV genotypes in this region were HPV16, 52, 58, 56, and 51. Notably, HR-HPV exhibited the highest prevalence in the older age group, suggesting persistent oncogenic risk in older populations. Acknowledgements Acknowledgments. We thank the Gynecology Clinic of the First Affiliated Hospital of Bengbu Medical University for their support in sample collection; and Professor Xu for his professional guidance. This article was approved by the Ethics Committee of Bengbu Medical University (Approval No. BMU-IRB-2024-418). The authors declare no conflict of interest. Author contributions XH: Conceptualization, Methodology, Writing – Original Draft, Data collation, Formal analysis, Funding acquisition. MZ: prepared Figs. 1, 2 and 3. LW prepared Figs. 4, 5, 6 and 7.KY: Resources, Validation. TX: Data collation, Validation, Review and editing. YH: Review and editing, Funding acquisition, Project management. All authors reviewed the manuscript. Funding This study was supported by grants from the Science and Technology Department of Anhui Province (Project No. 202427b10020015) and The First Affiliated Hospital of Bengbu Medical University (Project No. 2023byzd057). Data availability The datasets generated during this study are available from the corresponding author upon reasonable request. Declarations Ethics approval and consent to participate Research involving humans was approved by the Ethics Committee of Bengbu Medical University(Approval No. BMU-IRB-2024-418). The study was conducted in accordance with local laws and institutional requirements. Because of the retrospective nature of the study, patients were not required to submit written informed consent. Consent for publication Not applicable. (This study utilized anonymized epidemiological data with no personally identifiable information.) Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Tao Xu, Email: taoxu@bbmc.edu.cn. Yu He, Email: byyfyhu@126.com. References Associated Data Data Availability Statement The datasets generated during this study are available from the corresponding author upon reasonable request.